Bioequivalence of zolpidem hemitartrate: new formulations of 5 mg SL, 10 mg and 12.5 mg XR and comparison of their bioavailabilities
DOI:
https://doi.org/10.34119/bjhrv7n2-174Keywords:
zolpidem, bioequivalence, sublingual tablet, LC-MS/MS, hypnoticAbstract
Objective: To evaluate pharmaceutical bioequivalence between two formulations of 5 mg zolpidem hemitartrate sublingual and, 10 and 12.5 mg extended-release formulations tablets in healthy subjects under fasting and fed conditions. Methods: An open label, monocentric, randomized, 2 x 2 crossover study in 40 healthy adults under fasting conditions comparing two formulations of zolpidem 5mg sublingual tablets. Analyte concentrations in human plasma were determined using a validated liquid chromatography with a tandem mass spectrometer detector method (LC-MS/MS). The same design was utilized to evaluate the other formulations.
Results: Statistical analysis has determined geometric mean of test / reference ratio, confidence intervals, and power of the test to the pharmacokinetic parameters Cmax, AUC0-t, and AUC0-∞. The geometric mean ratio (90%CI) of the test drug/reference drug for zolpidem 5mg were 99.89 to 113.57% for Cmax, 97.15% to 108.40% for AUC0-t, and 97.22% to 108.13% for AUC0-∞. Power of the test was 99.35% for Cmax and 100% AUC0-t, and AUC0-∞. Conclusion: Both test and reference are bioequivalent for all formulations and, therefore, they are interchangeable, according to the Brazilian criteria (Anvisa resolution RE nº 1170/2006), since confidence intervals for Cmax and AUC0-t ratios were within 80% and 125%.
References
Poyares D, Jr L, Tavares S, Barros-Vieira S. Sleep Promoters and Insomnia. Revista brasileira de psiquiatria (São Paulo, Brazil : 1999). 2005;27 Suppl 1:2-7.
(INCB) INCB. Assessments of Psychotropic Substances 2022 [updated 05-Aug-2022. Available from: https://www.incb.org/documents/Psychotropics/assessment/august/Assesments_-_generated_on_-_05-08-22.pdf.
EMS-Sigma-Pharma-Ltda. Patz®S L (Hemitartarato De Zolpidem). Bula Do Medicamento. Responsável Técnico Adriano Pinheiro Coelho Crf/Sp N° 22.883. Disponível Em: Https://Consultas.Anvisa.Gov.Br/#/Bulario/Q/?Nomeproduto=Patz. Acesso Em 15/08/2022. 2021.
Yang LP, Deeks ED. Sublingual Zolpidem (Edluar; Sublinox). CNS Drugs. 2012;26(11):1003-10.
Staner C, Joly F, Jacquot N, Vlasova ID, Nehlin M, et al. Sublingual Zolpidem in Early Onset of Sleep Compared to Oral Zolpidem: Polysomnographic Study in Patients with Primary Insomnia. Curr Med Res Opin. 2010;26(6):1423-31.
Valente KD, Hasan R, Tavares SM, Gattaz WF. Lower Doses of Sublingual Zolpidem Are More Effective Than Oral Zolpidem to Anticipate Sleep Onset in Healthy Volunteers. Sleep Med. 2013;14(1):20-3.
Vlase L, Popa A, Neag M, Muntean D, Baldea I, et al. Pharmacokinetic Interaction between Zolpidem and Carbamazepine in Healthy Volunteers. J Clin Pharmacol. 2011;51(8):1233-6.
Vlase L, Popa A, Neag M, Muntean D, Leucuta SE. Pharmacokinetic Interaction between Zolpidem and Ciprofloxacin in Healthy Volunteers. Eur J Drug Metab Pharmacokinet. 2011;35(3-4):83-7.
Vlase L, Popa A, Neag M, Muntean D, Achim M, et al. Effect of Fluvoxamine on the Pharmokinetics of Zolpidem: A Two-Treatment Period Study in Healthy Volunteers. Clin Exp Pharmacol Physiol. 2012;39(1):9-12.
Staner L, Danjou P, Luthringer R. A New Sublingual Formulation of Zolpidem for the Treatment of Sleep-Onset Insomnia. Expert Rev Neurother. 2012;12(2):141-53.
FDA. Food and Drug Administration. Drug Approval Package. Ambien (Zolpidem Tartrate) Tablets. Company: Lorex Pharmaceuticals. Approval Date: 12/16/1992. [Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/019908_s000_ambientoc.cfm.
FDA. Food and Drug Administration. Drugs@Fda: Fda-Approved Drugs. Edluar. Zolpidem Tartrate. Mylan Speciality Lp. [Available from: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021997.
ANVISA. Agência Nacional De Vigilância Sanitária. Consultas. Registro De Produto. Stilnox. Sanofi-Aventis Farmacêutica Ltda. Data Do Registro: 20/08/2007. 2007 [Available from: https://consultas.anvisa.gov.br/#/medicamentos/25351410479200633/?nomeProduto=stilnox&substancia=21257
Langtry HD, Benfield P. Zolpidem. A Review of Its Pharmacodynamic and Pharmacokinetic Properties and Therapeutic Potential. Drugs. 1990;40(2):291-313.
Roth T, Krystal A, Steinberg FJ, Singh NN, Moline M. Novel Sublingual Low-Dose Zolpidem Tablet Reduces Latency to Sleep Onset Following Spontaneous Middle-of-the-Night Awakening in Insomnia in a Randomized, Double-Blind, Placebo-Controlled, Outpatient Study. Sleep. 2013;36(2):189-96.
ANVISA. Agência Nacional De Vigilância Sanitária. Notificações De Farmacovigilância 2022 [Available from: https://www.gov.br/anvisa/pt-br/acessoainformacao/dadosabertos/informacoes-analiticas/notificacoes-de-farmacovigilancia.
FDA. Food and Drug Administration. Fda Adds Boxed Warning for Risk of Serious Injuries Caused by Sleepwalking with Certain Prescription Insomnia Medicines [Available from: https://www.fda.gov/drugs/drug-safety-and-availability/fda-adds-boxed-warning-risk-serious-injuries-caused-sleepwalking-certain-prescription-insomnia#:~:text=Health%20care%20professionals%20should%20not,to%20serious%20injuries%20or%20death.
FDA. Food and Drug Administration. Fda Approves New Label Changes and Dosing for Zolpidem Products and a Recommendation to Avoid Driving the Day after Using Ambien Cr [Available from: https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-approves-new-label-changes-and-dosing-zolpidem-products-and.
ANVISA. Agência Nacional De Vigilância Sanitária. Lista 1 – Forma De Administração (Formas Farmacêuticas De Liberação Imediata). Resolução - Re Nº 1170, De 19 De Abril De 2006. Atualizada Em 31/03/2022. 2022 [Available from: https://www.gov.br/anvisa/pt-br/setorregulado/regularizacao/medicamentos/equivalencia-terapeutica/bioequivalencia/listas.
Agência Nacional De Vigilância Sanitária. Resolução - Rdc Nº 27, De 17 De Maio De 2012. Dispõe Sobre Os Requisitos Mínimos Para a Validação De Métodos Bioanalíticos Empregados Em Estudos Com Fins De Registro E Pós-Registro De Medicamentos., (2012).
Barkin RL. Zolpidem Extended-Release: A Single Insomnia Treatment Option for Sleep Induction and Sleep Maintenance Symptoms. Am J Ther. 2007;14(3):299-305.
Neubauer DN. Zolpimist: A New Formulation of Zolpidem Tartrate for the Short-Term Treatment of Insomnia in the Us. Nat Sci Sleep. 2010;2:79-84.
Neubauer DN, Pandi-Perumal SR, Spence DW, Buttoo K, Monti JM. Pharmacotherapy of Insomnia. J Cent Nerv Syst Dis. 2018;10:1179573518770672.
de Haas SL, Schoemaker RC, van Gerven JM, Hoever P, Cohen AF, et al. Pharmacokinetics, Pharmacodynamics and the Pharmacokinetic/ Pharmacodynamic Relationship of Zolpidem in Healthy Subjects. J Psychopharmacol. 2010;24(11):1619-29.
Abad VC, Guilleminault C. Insomnia in Elderly Patients: Recommendations for Pharmacological Management. Drugs Aging. 2018;35(9):791-817.
Salva P, Costa J. Clinical Pharmacokinetics and Pharmacodynamics of Zolpidem. Therapeutic Implications. Clin Pharmacokinet. 1995;29(3):142-53.
Qaseem A, Kansagara D, Forciea MA, Cooke M, Denberg TD, et al. Management of Chronic Insomnia Disorder in Adults: A Clinical Practice Guideline from the American College of Physicians. Ann Intern Med. 2016;165(2):125-33.
Agência Nacional De Vigilância Sanitária. Resolução - Re 1.170, De 19 De Abril De 2006. Guia Para Provas De Biodisponibilidade Relativa/Bioequivalência De Medicamentos., (2006).
Mendes GD, Pereira TDS, Rodrigues JC, Santos EM, Souza MR, et al. Comparative Bioavailability of Two Zolpidem Hemitartrate Formulations in Healthy Human Brazilian Volunteers Using High-Performance Liquid Chromatography Coupled to Tandem Mass Spectrometry. Biomed Chromatogr. 2020;34(4):e4731.
Allard S, Sainati SM, Roth-Schechter BF. Coadministration of Short-Term Zolpidem with Sertraline in Healthy Women. J Clin Pharmacol. 1999;39(2):184-91.
Li CT, Su TP, Wang Y, Lee B, Toh M, et al. Pharmacokinetics of a Novel Zolpidem Nasal Spray for Rapid Management of Insomnia: First Trial in Humans. J Clin Sleep Med. 2016;12(11):1453-9.
Park J-S, Myung JH, Wang H-S, Koo J, Cho W-K, et al. Pharmacokinetic and Bioequivalence Study of Zolpidem Tartate in Healthy Volunteers. Journal of Pharmaceutical Investigation. 2011;41:191-6.
Andreas CJ, Pepin X, Markopoulos C, Vertzoni M, Reppas C, et al. Mechanistic Investigation of the Negative Food Effect of Modified Release Zolpidem. Eur J Pharm Sci. 2017;102:284-98.
Greenblatt DJ, Harmatz JS, Singh NN, Roth T, Harris SC, et al. Influence of Food on Pharmacokinetics of Zolpidem from Fast Dissolving Sublingual Zolpidem Tartrate Tablets. J Clin Pharmacol. 2013;53(11):1194-8.
Guimaraes CL, Galvinas PAR, Baratta JA, Pinto GA, Brandão AH, et al. Pharmacokinetic Analysis and Bioequivalence of Finasteride and Doxazosin Formulated in a Single Tablet in Comparison with the Corresponding Single Agents. Brazilian Journal of Health Review. 2023;6(3):8649-61.
Schramm SG, Guimarães CL, Rezende VM, Sverdloff CE, Enguel V, et al. Comparative Bioavailability and Bioequivalence of Two 400 Mg Moxifloxacin Tablet Products after Single Dose Administration in Healthy Volunteers under Fasting Conditions. Brazilian Journal of Health Review. 2024;7(1):4720-32.
Reddy DC, Bapuji AT, Rao VS, Himabindu V, Ravinder S. A Rapid and Highly Sensitive Uplc-Ms-Ms Method for the Quantification of Zolpidem Tartrate in Human Edta Plasma and Its Application to Pharmacokinetic Study. J Chromatogr Sci. 2012;50(6):538-46.
Byeon JY, Lee HI, Lee YJ, Lee JE, Kim SH, et al. Determination of Zolpidem in Human Plasma by Liquid Chromatography-Tandem Mass Spectrometry for Clinical Application. J Chromatogr B Analyt Technol Biomed Life Sci. 2015;986-987:129-34.
